| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Cohort Study |
| Article Title |
Intermediate-advanced hepatocellular carcinoma in Argentina: Treatment and survival analysis
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Federico Piñero, Sebastian Marciano, Nora Fernández, Jorge Silva, Margarita Anders, Alina Zerega, Ezequiel Ridruejo, Gustavo Romero, Beatriz Ameigeiras, Claudia D'Amico, Luis Gaite, Carla Bermudez, Virginia Reggiardo, Luis Colombato, Adrián Gadano and Marcelo Silva |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Federico Piñero, MD, MSc, Academic Research, Doctor, Doctor, Hepatology and Liver Transplant Unit, Hospital Universitario Austral, Av. Presidente Perón 1500, Pilar, Buenos Aires B1629HJ, Argentina. fpinerof@cas.austral.edu.ar |
| Key Words |
Hepatocellular carcinoma; Therapeutics; Survival; Real-life |
| Core Tip |
Trans-arterial chemoembolization and systemic treatment with sorafenib are the standards of treatment for patients with intermediate and advanced stage hepatocellular carcinoma (HCC). The rise of new current therapeutic modalities such as radioembolization, the combination of antiangiogenic agents with locoregional therapies and other first and second line systemic options, open up a new paradigm for the treatment of HCC. In this dual cohort study, we describe the treatments performed in the real life setting before the approval of these new systemic options. Our real-data outcomes, lower than expected, highlight unmet needs and improvement areas in the daily practice prior to the introduction of new treatments for HCC. |
| Publish Date |
2019-07-19 12:39 |
| Citation |
Piñero F, Marciano S, Fernández N, Silva J, Anders M, Zerega A, Ridruejo E, Romero G, Ameigeiras B, D’Amico C, Gaite L, Bermúdez C, Reggiardo V, Colombato L, Gadano A and Silva M. Intermediate-advanced hepatocellular carcinoma in Argentina: Treatment and survival analysis. World J Gastroenterol 2019; 25(27): 3607-3618 |
| URL |
https://www.wjgnet.com/1007-9327/full/v25/i27/3607.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v25.i27.3607 |
